Price$8.51-0.36 (-4.00%)
01:30 PM07:45 PM
News · 26 weeks49-77%
2026-04-192026-10-11
Mix2590d
- Insider11(44%)
- Other5(20%)
- Leadership3(12%)
- SEC Filings3(12%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- INSIDERChief Business Officer D'Silva Andrew J. covered exercise/tax liability with 414 shares, decreasing direct ownership by 0.42% to 99,246 units (SEC Form 4) (withholding obligation)4 - OptimizeRx Corp (0001448431) (Issuer)
- ANALYSTB. Riley Securities resumed coverage on OptimizeRx with a new price targetB. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $11.00
- PROptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPathWALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk’s supply path optimization solution, making OptimizeRx’s authenticated point of care inventory available directly to advertisers using The Trade Desk’s leading, data-driven demand side platform (DSP). Through OpenPath, advertisers using The Trade Desk will gain direct access to OptimizeRx’s proprietary network of more than 400 electronic health record (EHR) and e-prescribe
- PROptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience IntelligenceWALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points has expanded its patent-pending, AI-powered Natural Language Audience Builder (NLAB) tool to allow media planners and buyers to build both claims-grade HCP audiences and privacy-safe direct-to-consumer (DTC) audiences in the same workflow, from a shared plain-language prompt. This expansion adds OptimizeRx’s Micro-Neighborhood® Targeting (MNT) audiences to NLAB, transforming NLAB from an HCP audience-building
- PROptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth ConferenceWALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced that management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 10, 2026, in New York, NY. To request a meeting or for more details about the conferences please reach out to your institutional contact. About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients
- INSIDERChief Business Officer D'Silva Andrew J. covered exercise/tax liability with 1,432 shares, decreasing direct ownership by 1% to 99,660 units (SEC Form 4) (withholding obligation)4 - OptimizeRx Corp (0001448431) (Issuer)
- PROptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company AdvisorWALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor. Sarich brings nearly 30 years of extensive experience within global healthcare, life sciences and pharmaceutical commercialization to the advisory board, including deep expertise in data, analytics, and artificial intelligence. Sarich served as the Chief Commercial Data Science Officer at Johnson & Johnson where he advanced the company’s scientific and c
- INSIDERChief Executive Officer Silvestro Stephen L was granted 79,200 shares, increasing direct ownership by 43% to 262,751 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Business Officer D'Silva Andrew J. was granted 57,600 shares, increasing direct ownership by 132% to 101,092 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Legal & Admin Officer Odence-Ford Marion was granted 57,600 shares, increasing direct ownership by 64% to 148,007 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Merrell Brendan W. was granted 57,600 shares, increasing direct ownership by 229% to 82,787 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Merrell Brendan W. covered exercise/tax liability with 1,020 shares, decreasing direct ownership by 4% to 25,187 units (SEC Form 4) (for tax liability)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Executive Officer Silvestro Stephen L covered exercise/tax liability with 1,737 shares, decreasing direct ownership by 0.94% to 183,551 units (SEC Form 4) (for withholding tax)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Legal & Admin Officer Odence-Ford Marion covered exercise/tax liability with 1,529 shares, decreasing direct ownership by 2% to 90,407 units (SEC Form 4) (tax withholding)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Business Officer D'Silva Andrew J. covered exercise/tax liability with 1,243 shares, decreasing direct ownership by 3% to 43,492 units (SEC Form 4) to satisfy withholding obligation4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Finance & Strat Officer Stelmakh Edward covered exercise/tax liability with 1,381 shares, decreasing direct ownership by 1% to 121,791 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- SECSEC Form S-8 filed by OptimizeRx CorporationS-8 - OptimizeRx Corp (0001448431) (Filer)
- SECSEC Form SCHEDULE 13G filed by OptimizeRx CorporationSCHEDULE 13G - OptimizeRx Corp (0001448431) (Subject)
- SECSEC Form 10-Q filed by OptimizeRx Corporation10-Q - OptimizeRx Corp (0001448431) (Filer)
- SECOptimizeRx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - OptimizeRx Corp (0001448431) (Filer)
- PROptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of GrowthThe Company Names Andy D’Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027 Planned Transition Reflects Strong Succession Planning and Deep Leadership Bench WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading healthcare technology company enabling life sciences organizations to deliver smarter, more personalized engagement across the healthcare ecosystem, today announced a finance leadership transition that reflects the Company’s disciplined succession planning, deep leadership bench, and confidence in its long-term strategy. The Company’s Board of Directors has
- PROptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance– Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million– Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of principal since inception WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results
- PROptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ETWALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, will hold a conference call on Wednesday, August 12, 2026, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2026. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Wednesday, August 12, 2026 Time: 4:3
- PROptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing OfficerWALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings more than two decades of pharmaceutical marketing experience to the leadership team, including deep expertise in point of care (POC) media strategy, analytics, and optimization across leading healthcare marketing organizations. Most recently, Bast served as Executive Vice President, Investment Marketplace at Publicis Health Media, where s
- SECSEC Form SCHEDULE 13G filed by OptimizeRx CorporationSCHEDULE 13G - OptimizeRx Corp (0001448431) (Subject)
OPRX FAQ
6 questionsWhat does OptimizeRx Corporation do?
OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages. The company also offers brand support...Where does OPRX stock trade?
OptimizeRx Corporation (OPRX) is listed on NASDAQ.What sector and industry is OPRX in?
OptimizeRx Corporation operates in the Real Estate sector.What are analysts saying about OPRX?
OptimizeRx Corporation has had 8 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1100.00 price target on 2026-09-29.What companies are similar to OPRX?
Notable peers in the same industry include V (Visa Inc.), MA (Mastercard Incorporated), BABA (Alibaba Group Holding Limited), ACN (Accenture plc), UBER (Uber Technologies Inc.). Compare OPRX side-by-side with any of them on Quantisnow.How can I track OPRX on Quantisnow?
Quantisnow aggregates OptimizeRx Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OPRX to receive live email and push alerts on every new disclosure.